Table 3.
Immunological characteristics among SIR and non-SIR participants at year 3 after initiating ART.
| Age, sex and baseline CD4 count matched case-control |
|||
|---|---|---|---|
| SIR | Non-SIR | P-value1 | |
| Number of participants | N = 17 | N = 24 | |
| Sex, n (%) | 0.80 | ||
| Female | 3 (17.7) | 5 (20.8) | |
| Male | 14 (82.3) | 19 (79.2) | |
| Age in years, median (IQR) | 36 (34–44) | 37(32–42) | 0.72 |
| BMI, median (IQR) | 20.6 (19.3–21.9) | 21.1 (17.9–24.2) | 0.70 |
| Pre-ART CD4 count cells/mm3, median (IQR) | 0.837 | ||
| ≤100 | 4 (23.5) | 5 (20.8) | |
| 101–200 | 13 (76.5) | 19 (79.2) | |
| Pre-ART HIV-RNA level in log10copies/mL, median (IQR) | 4.32 (4.2–4.8) | 5.13 (4.6–5.6) | 0.003 |
| HBV co-infection, n (%) | 3/16 (18.8) | 10/20 (50.00) | 0.083 |
| HCV co-infection, n (%) | 3/16 (18.8) | 0/19 (0.00) | 0.05 |
| IL-7 <13.6 pg/mL, n (%) | 15 (88.2) | 17 (70.8) | 0.262 |
| sCD14 (Log10pg/mL), mean (95% CI) | 6.23 (6.18–6.27) | 6.27 (6.21–6.39) | 0.04 |
| CD4/CD8 ratio, mean (95% CI) | 0.27 (0.22–0.37) | 0.41 (0.29–0.51) | 0.010 |
| CD8 count, mean (95% CI) | 514 (358–695) | 876 (652–1127) | 0.0003 |
| CD8+CCR7-CD45RA-PD1-, mean (95% CI) | 25.1 (20.6–27.9) | 34.9 (28.3–42.5) | 0.02 |
| CD8+CCR7-CD45RA-PD1+, mean (95% CI) | 74.2 (70.5–78.7) | 65.1 (57.2–70.3) | 0.02 |
| CMV DNA, copies/mL, n (%) | |||
| <44 (lower limit of detection) | 17 (100.0) | 24 (100.0) | N/A |
| ≥44 | 0 (0.0) | 0(0.0) | |